The Weekly Roundup: September 30-October 4

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Interview Intersection: Expert Interviews From September 2024

Dermatology Times is recapping our top expert interviews from the month of September.

Dermatology Times September 2024 Recap

Dermatology Times is looking back on the top stories in dermatology from the month of September.

2-Year Study Affirms Bimekizumab's Efficacy in Hidradenitis Suppurativa

Nearly 44.2% of patients achieved HiSCR100, indicating a complete resolution of HS symptoms by the end of the 2-year period.

Recognizing Key Differences Between Atopic Dermatitis and Prurigo Nodularis

Gil Yosipovitch, MD, reviews differences including lesion appearance, cytokine pathways, treatment options, and more.

Dermatology Conferences and Meetings Calendar 2024: October

Dermatology Conferences and Meetings Calendar 2024: October

Vitiligo News: The Year Thus Far

Catch up on the latest news on vitiligo advancements in 2024.

Analyzing Efficacy and Safety in Diverse Clinical Trials: New Roflumilast Data

After releasing promising data from several clinical trials, Burnett discussed the importance of studying efficacy and safety across diverse populations.

Promising Long-term Results for ESK-001 in Psoriasis

The company plans to release full 52-week OLE data for ESK-001 in early 2025, building on positive interim results.

Late-Breaking Data: 40-Week Efficacy and Safety of Oral Povorcitinib for Prurigo Nodularis

Shawn Kwatra, MD, presented the Incyte data at EADV 2024.

Dermatology Times September 2024 Print Recap

Learn more about the in-depth topics covered in the September 2024 print issue of Dermatology Times.

UCB Announces Head-to-Head Trial Comparing Bimekizumab and Risankizumab

This marks the first head-to-head trial of an IL-17A/F inhibitor against an IL-23 inhibitor in psoriatic arthritis treatment.

Monobenzone May Heighten Oxidative Stress and Systemic Health Concerns, Study Suggests

Researchers found that MBEHQ treatment increased oxidative stress and proinflammatory cytokines IL-1β and IL-18 in patients with vitiligo.

Biosimilars Offer VA Cost Savings in Psoriasis Treatment

Enhanced education can reduce uncertainty among both patients and providers, with pharmacists playing a key role as primary sources of patient information.

Review Explores Abrocitinib’s Off-Label Uses

Researchers behind the review suggested that future research should prioritize large-scale trials to confirm abrocitinib's long-term safety and efficacy in various skin disorders.

Advances in Vitiligo Treatment Focus on Immunomodulatory Pathways, Cellular Grafting, and Emerging Drug Targets

A review examined how vitiligo treatments aim to restore melanocyte function through grafting, phototherapy, immune regulation, antioxidants, and stem cell research.

Addressing Causes of Female Hair Loss and Exploring Preventative Measures

This expert review explores the multifaceted causes of female hair loss—hormonal imbalances, inflammation, nutrient deficiencies, aging, and oxidative stress—and explores non-pharmaceutical interventions.

New Insights on Treating Pigmented Actinic Keratoses with Laser Technology

A recent study indicated that 43.3% of lesions achieved a high efficacy score following Alexandrite laser therapy.

Clinical Features and Cytokine Pathways in Prurigo Nodularis vs Atopic Dermatitis

Jason Hawkes, MD, MS, emphasized the importance of biologic treatments transforming the management of both prurigo nodularis and atopic dermatitis.

Thyroid Disorders and Their Link to Alopecia Areata

Hypothyroidism and Hashimoto's thyroiditis were found to significantly increase the risk of developing AA, unlike hyperthyroidism.

9 Months of Treatment With Tralokinumab Results in Improved QoL, Itch, and Sleep

A poster presented at EADV 2024 explored patient-reported outcomes from. the TRACE study for AD.

Significant Proportion of Patients With AD Maintain Stable EASI With Tralokinumab Treatment

More than half of treatment responders maintained stable EASI ≤ 7, according to a poster from EADV.

GPP Therapies: Comparing Efficacy and Safety of Secukinumab and Ustekinumab

While researchers found both therapies effective in long-term use, they stated secukinumab showed quicker improvements in QoL.